慢性下気道感染症に対する Ritipenem acoxil と Cefotiam hexetil の薬効比較試験成績

saitou   atusi,saitou   rei,kawakami   yosikazu,yamaguti   eturou,koba   hiroyuki,abe   syousaku,daidou   mituhide,hiraga   hiroaki,kikuti   kenzirou,oosaki   nou sin,matumoto   hiroyuki,inoue   hirosi nisi,yosida   masami,mouri   takasi,kobayasi   hitosi,itou   takasi,bandou   takesi,takeuti   ken'iti,heiya   haruhito,tanifuzi   yukio,tanno   yasuo,sirato   kunio,takahasi   makoto,sakamoto   masahiro,nukiwa   tosihiro,watanabe   akira,satou   kazuo,nakamura   tosio,yanase   kenzi,dote   kunio,honma   mitunobu,itou   sinrou,ooisi   mei,fukuda   kiyosi,zhongzedun,kati   masataka,kobayasi   hiroyuki,sakayori   kyou,miura   hirosi,watanabe   syuu hirosi,simada   kaoru,oka   sin'iti,sugiyama   hirotaka,inamatu   takasi omoi,sano   yasuyuki,arai   yasuo,ootomo   syu,kobayasi   hideo,hisayosi ki   takasi han,tanaka   hiroyuki,sisido   harumi,tagami   syouko,dobasi   keiko,oyama   yuu,kudou   kouitirou,kosino   takesi,akiyama   jun,ookubo   takao,tani   kenzi,ikeda   daityuu,syouzi   akira,sen ba   jun,dayezi,honda   junrou,ikehara   kunihiko,irimaziri   syouitirou,matuoka   yasuo,kobana   mituo,matumoto   fumio,sakurai   iwa,odagiri   sigeki,ogura   takasi,takahasi   hirosi,arakawa   masaaki,wada   kouiti,iwata   fumihide,simazu   yosinori,sega   hiroyuki,tukada   hiroki,kawasima   suu,aoki   nobuki,suzuki   yasusi minoru,sekine   ri,satou   atuhiko,tida   kingo,iwata   masatosi,siti   izumi,yasuda   kazumasa,torigai   katutaka,takagi   kenzou,watanabe   yosiaki,taniguti   hiroyuki,yamasita   naohiro,usui   isao,izumi   saburou,kuze   fumiyuki,bandou   kenzi,Dashanzhenyi Lang,nisiyama   hideki,sugita   kouwa,horikawa   sadao,kisimoto   tyuuzou,tanio   kitirou,ikeda   satosi yuki,itou   masami,okumoto   tuyosi,yonetu   sei bun,miki   fumio,ookawa   kentarou,nakazima   sigenori,narita   kou kei,sawaki   masayosi,mikasa   keiiti,higasino   kazuya,nakano   takasi,mae bou   akio,yosimoto   suu hiko,sonoda   takasi,nomura   sigeo,yamaguti   kazuyuki,tokumoto   hirosi,nakagawa   masakiyo,hirabayasi   masataka,togawa   naoki,yosida   masao,kawai   yositaka,fuku sima   rinzou,okimoto   zirou,matusima   tosiharu,kimura   tan,佐々木 孝夫,matumoto   yukio,yamaki ko   mitirou,isioka   sin'iti,kuwahara   masao,wangyuexinhong,miyazawa   teruomi,yanagida   ziturou,arida   ken'iti,daidou   kazuhiro,ezima   tuyosi,sone   saburou,tani   kenzi,miki   satosi,sawae   yosirou,takagi   kouzi,yosida   minoru,aritomi   takamiti,ooizumi   koutarou,itikawa   youitirou,siroisi   tuneaki,kawara   seisi,kawaguti   sinzou,kawa yama   satoru takasi,satou   nou kei,honda   yosiaki,isibasi   bon osu,takamoto   sei si,kaziki   syou,harada   yasuko,yamada   hozumi,fuzisawa   nobumitu,andou   masayuki,kan   moritaka,tutii   tosinori,tokunaga   katumasa,sima   kiyosi,gaku naka   tai otto,hara   kouhei,kouno   sigeru,kaku   mituo,koga   nobuhiro,inoue   yuuiti,yamasita   yuuko,bantianshenwu,fuzii   tuyosi,irifune   kenzi,kakou   wa nori,miyazaki   yositugu,watanabe   takasi,fuku sima   yosifumi,matumoto   yosi kura,nagatake   tuyosi,sakamoto   yoku,tao   misao,yamasita   hirosi,takasi sugi   masakazu,akiyama   jou tou tukasa,fuzisita   mikio,nasu   kati,yamazaki   touru,gotou   youitirou,nakama   kaoru,inoue   souiti,matukura   sigeru,masumoto   hideo,saitou   atusi,fukuhara   hirosi,takesi yama   masao,oyakawa   tomi nori,deguti   kouiti,nakazima   mituyosi

慢性下気道感染症に対する Ritipenem acoxil と Cefotiam hexetil の薬効比較試験成績

1996

To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against chronic lower respiratory tract infections, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as a control drug. RIPM-AC was orally administered at 200 mg, and CTM-HE at 400 mg, t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 202, of which 151 cases (RIPM-AC group: 75, CTM-HE group: 76) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent+good) were 85.3% (64/75) in the RIPM-AC group and 80.3% (61/76) in the CTM-HE group. There was no significant difference between the two groups, hence the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 50.0% (13/26) in the RIPM-AC group and 75.0% (18/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 10 cases (11.0%) of the RIPM-AC group and 10 cases (10.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 8 cases(9.5%) of the RIPM-AC group and in 14 cases (16.7%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects and abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 73 cases (80.2%) and CTM-HE in 71 cases (77.2%), with no significant difference. 4. The usefulness rates (markedly useful+useful) were 79.5% (62/78) in the RIPM-AC group and 76.9% (60/78) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of chronic lower respiratory tract infections.

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations